Kocaturk, E. Et Al. 2019. Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: Are there specific patient characteristics or biomarkers to indicate response to treatment?. Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , (Lisbon, Portugal), 484-485.

Kocaturk, E., Baskan, E. B., Engin, B., Ozdemir, M., Kucuk, O. S., Can, P., ... Ornek, S.(2019). Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: Are there specific patient characteristics or biomarkers to indicate response to treatment? . Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) (pp.484-485). Lisbon, Portugal

Kocaturk, E. Et Al. "Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: Are there specific patient characteristics or biomarkers to indicate response to treatment?," Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Lisbon, Portugal, 2019

Kocaturk, E. Et Al. "Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: Are there specific patient characteristics or biomarkers to indicate response to treatment?." Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , Lisbon, Portugal, pp.484-485, 2019

Kocaturk, E. Et Al. (2019) . "Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: Are there specific patient characteristics or biomarkers to indicate response to treatment?." Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , Lisbon, Portugal, pp.484-485.

@conferencepaper{conferencepaper, author={E. Kocaturk Et Al. }, title={Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: Are there specific patient characteristics or biomarkers to indicate response to treatment?}, congress name={Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI)}, city={Lisbon}, country={Portugal}, year={2019}, pages={484-485} }